Table 1.
Genome-wide association studies used to obtain the summary statistics
| Phenotype | Sample size | Cases | Controls | Sourcea |
|---|---|---|---|---|
| Exposures | ||||
| Type 2 diabetesb | 74,124 | 824,006 | Mahajan et al, 2018 | |
| Type 2 diabetesc | 228,499 | 1,178,783 | Vujkovic et al, 2020 | |
| HbA1c | 344,182 | Neale lab 2020d | ||
| Outcomes | ||||
| Disease outcomes | ||||
| Chronic kidney disease | 64,164 | 561,055 | Wuttke et al, 2019 | |
| Coronary artery disease | 60,801 | 123,504 | Nikpay et al, 2015 | |
| HF | 47,309 | 930,014 | Shah et al, 2020 | |
| Ischaemic stroke | 34,217 | 406,111 | Malik et al, 2018 | |
| Cardiometabolic traits | ||||
| Alanine aminotransferase | 344,136 | Neale lab 2020 | ||
| BMI | 484,680 | Pulit et al. 2018 | ||
| CRP | 343,524 | Neale lab 2020 | ||
| Systolic BP | 745,820 | Evangelou et al. 2018 | ||
| Lipids | ||||
| HDL-C | 315,133 | Neale lab 2020 | ||
| LDL-C | 343,621 | Neale lab 2020 | ||
| Triacylglycerol | 343,992 | Neale lab 2020 | ||
aThe references for the original studies are given in the ESM
bUsed for co-localisation analysis
cUsed for MR analysis
dAll Neale lab 2020 GWAS summary statistics are available at: http://www.nealelab.is/uk-biobank
LDL-C, LDL-cholesterol